News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Change in the number of shares and votes in Egetis Therapeutics

October 31, 2023

Stockholm, Sweden, October 31, 2023. The number of shares and votes in Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (STO: EGTX) has increased in the month of October as a result of the private placement of shares announced on October 10, 2023.
The total number of shares and votes has increased by 42,982,331, from 249,589,128 to 292,571,459. The share capital has increased by approximately SEK 2,262,228.791300, from approximately SEK 13,136,274.795261 to approximately SEK 15,398,503.586561.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10